1063 related articles for article (PubMed ID: 29104284)
41. Selective JAK1 inhibitors for the treatment of inflammatory bowel disease.
Nielsen OH; Boye TL; Gubatan J; Chakravarti D; Jaquith JB; LaCasse EC
Pharmacol Ther; 2023 May; 245():108402. PubMed ID: 37004800
[TBL] [Abstract][Full Text] [Related]
42. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Kotyla PJ; Islam MA; Engelmann M
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
[TBL] [Abstract][Full Text] [Related]
43. Translating JAKs to Jakinibs.
Gadina M; Chisolm DA; Philips RL; McInness IB; Changelian PS; O'Shea JJ
J Immunol; 2020 Apr; 204(8):2011-2020. PubMed ID: 32253269
[TBL] [Abstract][Full Text] [Related]
44. Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.
Kim H
Expert Rev Clin Immunol; 2024 Jun; 20(6):589-602. PubMed ID: 38299575
[TBL] [Abstract][Full Text] [Related]
45. Synthesis and clinical application of small-molecule inhibitors of Janus kinase.
Zhang JY; Sun JF; Nie P; Herdewijn P; Wang YT
Eur J Med Chem; 2023 Dec; 261():115848. PubMed ID: 37793326
[TBL] [Abstract][Full Text] [Related]
46. An Update on JAK Inhibitors.
Musumeci F; Greco C; Giacchello I; Fallacara AL; Ibrahim MM; Grossi G; Brullo C; Schenone S
Curr Med Chem; 2019; 26(10):1806-1832. PubMed ID: 29589523
[TBL] [Abstract][Full Text] [Related]
47. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
48. Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases.
Bach J; Eastwood P; González J; Gómez E; Alonso JA; Fonquerna S; Lozoya E; Orellana A; Maldonado M; Calaf E; Albertí J; Pérez J; Andrés A; Prats N; Carreño C; Calama E; De Alba J; Calbet M; Miralpeix M; Ramis I
J Med Chem; 2019 Oct; 62(20):9045-9060. PubMed ID: 31609613
[TBL] [Abstract][Full Text] [Related]
49. Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.
Alexander M; Luo Y; Raimondi G; O'Shea JJ; Gadina M
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056105
[TBL] [Abstract][Full Text] [Related]
50. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
Welsch K; Holstein J; Laurence A; Ghoreschi K
Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
[TBL] [Abstract][Full Text] [Related]
51. JAK Inhibitors for Atopic Dermatitis: An Update.
He H; Guttman-Yassky E
Am J Clin Dermatol; 2019 Apr; 20(2):181-192. PubMed ID: 30536048
[TBL] [Abstract][Full Text] [Related]
52. Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.
Hadjadj J; Frémond ML; Neven B
Front Immunol; 2021; 12():717388. PubMed ID: 34603291
[TBL] [Abstract][Full Text] [Related]
53. Targeting cytokine signaling in autoimmunity: back to the future and beyond.
Hirahara K; Schwartz D; Gadina M; Kanno Y; O'Shea JJ
Curr Opin Immunol; 2016 Dec; 43():89-97. PubMed ID: 27821272
[TBL] [Abstract][Full Text] [Related]
54. Emerging therapies for atopic dermatitis: JAK inhibitors.
Cotter DG; Schairer D; Eichenfield L
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
[TBL] [Abstract][Full Text] [Related]
55. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Danese S; Argollo M; Le Berre C; Peyrin-Biroulet L
Gut; 2019 Oct; 68(10):1893-1899. PubMed ID: 31227590
[TBL] [Abstract][Full Text] [Related]
56. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
57. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
Svoboda SA; Johnson N; Phillips M
Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
[TBL] [Abstract][Full Text] [Related]
58. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
[TBL] [Abstract][Full Text] [Related]
59. JAK inhibitors: Novel developments in management of ulcerative colitis.
Fiorino G; D'Amico F; Italia A; Gilardi D; Furfaro F; Danese S
Best Pract Res Clin Gastroenterol; 2018; 32-33():89-93. PubMed ID: 30060943
[TBL] [Abstract][Full Text] [Related]
60. JAK inhibitors in 2019, synthetic review in 10 points.
Muller R
Eur J Intern Med; 2019 Aug; 66():9-17. PubMed ID: 31178258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
